Objective-To define the mechanisms whereby methotrexate (MTX) manifests its effects in patients with rheumatoid arthritis. Methods-T and B cells from peripheral blood and rheumatoid synovial tissues, synovial adherent cells, and the human fibrosarcoma cell line HT1080 and its mutant (defective in an enzyme in the nucleotide salvage pathway) were tested for clonal growth when cultured with MTX. Normal human fibroblastsaFd those with a deficiency in a salvage paway were cultured with MTX in the presence or absence of purine and pyrimidine bases.
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Objective-To define the mechanisms whereby methotrexate (MTX) manifests its effects in patients with rheumatoid arthritis. Methods-T and B cells from peripheral blood and rheumatoid synovial tissues, synovial adherent cells, and the human fibrosarcoma cell line HT1080 and its mutant (defective in an enzyme in the nucleotide salvage pathway) were tested for clonal growth when cultured with MTX. Normal human fibroblastsaFd those with a deficiency in a salvage paway were cultured with MTX in the presence or absence of purine and pyrimidine bases.
Results-Clonal growth of T and B cells, but not synovial cells, was inhibited by clinically relevant concentrations ofMTX. Slowly proliferating fibroblast lines were resistant to MTX, whereas their rapidly proliferating counterparts were not. However, mutant fibroblast lines deficient in a salvage pathway were sensitive to MTX despite slow proliferation. Similarly, while skin fibroblasts were resistant to MTX, germline mutant fibroblasts deficient in a salvage pathway were sensitive to small concentrations ofMTX. Conclusion-T and B lymphocytes, but not synovial cells, may be the target of MTX in vivo. Resistance to MTX may be associated with slow proliferation and the ability to synthesise nucleotides via salvage pathways. MTX can inhibit proliferation of even slowly growing cells by restricting the supply of nucleotides obtained via a salvage pathway, by removal of purine and pyrimidine bases, or by inducing a deficiency in a salvage pathway. It may be possible to manipulate the therapeutic effect ofMTX by adjusting the amounts of purines and pyrimidines available to the cells in vivo.
(Ann Rheum Dis 1996; 55: 237-242)
Many reports in the 1980s described the efficacy of a low dose weekly pulse regimen of methotrexate (MTX) for the treatment of rheumatoid arthritis (RA), 1-3 and currently the long term effectiveness of MTX is widely accepted.' MTX has been markedly effective in RA patients who had been unresponsive to conventional treatments,1 7 and suppressive effects of MTX on the progression of radiographic changes in RA patients have also been observed. 4 8 Various mechanisms have been proposed to account for the beneficial effects of MTX in the management of RA. MTX modulates arachidonic acid metabolism in neutrophils from patients with active RA in such a way that the synthesis, release, and retention of lipoxygenase products are suppressed.9-12 MTX suppresses the proliferation of mitogen activated lymphocytes,'13-6 and inhibits the formation of methyl donor S-adenosylmethionine (SAM) and polyamines, which are important in cell mediated immune reactions.'3 The activity and production of interleukin-l may be suppressed by MTX,'7-'9 but the serum concentrations of tumour necrosis factor a and interleukin-6 are not related to the effectiveness of MTX.20 21 MTX induces an increase in the intracellular concentration of adenosine,22 23 To evaluate the role of salvage pathways in MTX resistance, a mutant HT1080 subline (HT108OTG), deficient in the purine salvage enzyme hypoxanthine phosphoribosyltransferase (HPRT), was selected from HT1080 by adding 2-5 ,ug/ml 6-thioguanine (Wako Pure Chemical Industry, Osaka, Japan).
The cells of HT1080 were separated by the cloning procedure into large colony forming and small colony forming subpopulations, and cloned in the presence of various concentrations of MTX. For the cloning, HT1080 and HT108OTG were inoculated at 2-20 cells/ well and SF-TY and MiTen at 10-50 cells/ well, into 96 well flat bottom plates. To examine the mechanism for MTX resistance in slowly proliferating ( (table 5 ). In addition, low concentrations of MTX completely inhibited the growth of both rapidly proliferating (large colony) and slowly proliferating (small colony) subpopulations of HT108OTG (table 5) .
EFFECTS OF MTX ON THE CLONAL GROWTH OF SKIN FIBROBLASTS
In common with the synovial adherent cells and the slowly proliferating subpopulation of HT1 080 cells, skin fibroblasts were resistant to MTX (table 6 ). In addition, clonal growth of a fibroblast line (MiTen) from a patient with genetic HPRT deficiency (Lesch-Nyhan syndrome) was completely inhibited by low concentrations of MTX, suggesting again that the salvage enzyme has an important role in MTX resistance (table 6) of methotrexate: **p < 001, whereas we used only clonal culturing, and they used synovial adherent cells at the first to third passages, whereas we used only fresh synovial single cells; it is possible that cells with greater proliferative capacity become more dominant after cell passage, and such cells could conceivably be more sensitive to the inhibitory effects of MTX.
Sensitivity to MTX appears to be largely dependent on the rate of proliferation of the cells, rather than on cell type, as the clonal growth of a rapidly proliferating (large colony forming) subpopulation of a human fibrosarcoma cell line, HT1080, was completely inhibited by low concentrations of MTX, while that of a slowly proliferating (small colony forming) subpopulation from the same line was not. In the latter line, the apparent resistance of synovial adherent cells to MTX in the present study may be explained by a low rate of proliferation.
Reduced transport of MTX through the cell 
